Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 9/20 | 0.45 |
| ▸ | BRD4 | O60885 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5648797 | 0.91 | FLT3 (0.45) | FLT3BRD4KMT2AMEN1POLB | |
| SCHEMBL5651321 | 0.91 | FLT3 (0.46) | FLT3BRD4 | |
| SCHEMBL5649700 | 0.89 | PRMT5 (0.42) | KMT2AMEN1POLBHTTSMN1; SMN2 | |
| SCHEMBL5651884 | 0.86 | FLT3 (0.48) | FLT3 | |
| SCHEMBL5651490 | 0.86 | FLT3 (0.45) | FLT3BRD4KMT2AMEN1POLB | |
| SCHEMBL5653401 | 0.85 | FLT3 (0.48) | FLT3POLBHTT | |
| SCHEMBL5649763 | 0.84 | TSHR (0.52) | KMT2AMEN1HTT | |
| SCHEMBL5649928 | 0.84 | FLT3 (0.48) | FLT3 | |
| SCHEMBL5652589 | 0.83 | FLT3 (0.49) | FLT3BRD4KMT2AMEN1POLB | |
| SCHEMBL5649910 | 0.82 | FLT3 (0.42) | FLT3BRD4KMT2ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | FLT3 1968/4885BRD4 833/4885KMT2A 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.